Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Short Interest Update

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 180,500 shares, a decrease of 32.6% from the January 15th total of 267,900 shares. Based on an average daily volume of 138,100 shares, the short-interest ratio is presently 1.3 days.

Medexus Pharmaceuticals Stock Down 1.6 %

Shares of OTCMKTS:MEDXF traded down $0.04 on Friday, reaching $2.17. 15,435 shares of the company’s stock were exchanged, compared to its average volume of 52,415. Medexus Pharmaceuticals has a fifty-two week low of $1.08 and a fifty-two week high of $3.88. The business’s 50-day moving average is $2.48 and its two-hundred day moving average is $2.04.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.